Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Literacy to Specific Drug Risks

The legacy domain of general health and science information has long served as a foundational resource for public understanding of medical conditions and therapeutic interventions. Within this broad context, audiences have historically accessed reliable overviews of drug mechanisms, disease prevalence, and preventive care guidelines. This heritage provides a necessary baseline for interpreting more specialized health risks that emerge from specific pharmaceutical exposures. Transitioning from this general framework, attention now turns to a particular area of clinical concern: the relationship between bisphosphonate therapy, specifically Fosamax (alendronate), and the development of osteonecrosis of the jaw. While the legacy context offers general principles of drug safety and bone physiology, the focus narrows here to a distinct exposure scenario. This pivot requires examining how prolonged use of this medication, commonly prescribed for osteoporosis, may be associated with a rare but serious condition affecting the mandible or maxilla. The shift from broad health literacy to this specific therapeutic exposure concern underscores the need for precise risk communication. In this transition, the emphasis moves from general awareness to the identification of patient populations who may face elevated risk due to cumulative drug exposure.

Understanding Fosamax and Its Approved Uses

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, consideration of drug discontinuation after 3 to 5 years of use is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section bridges the general health context to the specific risk of osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves delayed healing after dental procedures, such as tooth extraction or dental implant placement, and may be associated with local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is based on clinical examination and imaging, with the condition occurring spontaneously or in association with identifiable triggers.

Scientific Evidence Linking Fosamax to Osteonecrosis of the Jaw

Scientific evidence establishes a connection between Fosamax use and ONJ. The prescribing information for Fosamax states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Similarly, the labeling for Fosamax Plus D notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These reports are not isolated; they are part of a broader pharmacovigilance signal recognized by regulatory authorities. Mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacology as a bisphosphonate. Bisphosphonates, including alendronate (the active ingredient in Fosamax), inhibit osteoclast-mediated bone resorption. This suppression of bone turnover can impair the normal remodeling and repair processes in the jawbone. Research using animal models has provided insights into these mechanisms. A multiscale characterization of jawbone in estrogen-deficient rats treated with bisphosphonate (alendronate) showed effects on the jawbone, including changes in tissue mineral density distribution and mechanical stability of teeth in the alveolar socket (https://pubmed.ncbi.nlm.nih.gov/40345077/). This study aimed to understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw, providing comprehensive information on how these agents alter bone properties at multiple scales (https://pubmed.ncbi.nlm.nih.gov/40345077/). The findings suggest that bisphosphonate treatment can compromise the structural and mechanical integrity of the jawbone, potentially predisposing it to necrosis.

Risk Factors and Clinical Management

Risk factors for developing ONJ while taking Fosamax include invasive dental procedures such as tooth extraction, dental implants, and boney surgery; diagnosis of cancer; concomitant therapies like chemotherapy, corticosteroids, and angiogenesis inhibitors; poor oral hygiene; and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The adequacy of warnings regarding Fosamax and ONJ is addressed in the drug's labeling. The prescribing information includes a specific section titled '5.4 Osteonecrosis of the Jaw' that describes the condition, its association with bisphosphonates including Fosamax, and known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The labeling for Fosamax Plus D similarly contains this warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Causation-related considerations for affected patients involve evaluating the temporal relationship between Fosamax exposure and the development of ONJ. The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after stopping the drug, and a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse effect, it is not common in the general osteoporosis population. The timeline between exposure and documented harm can be variable. ONJ may occur after months or years of bisphosphonate use, and the risk appears to increase with longer duration of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients who develop ONJ, management includes discontinuation of the bisphosphonate if severe symptoms develop, and addressing local factors such as infection or dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the scientific evidence linking Fosamax to osteonecrosis of the jaw?

Scientific evidence includes reports in the prescribing information for Fosamax and Fosamax Plus D, which state that osteonecrosis of the jaw (ONJ) has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Additionally, animal studies have shown that alendronate can alter jawbone properties, potentially predisposing to necrosis (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the risk factors for developing osteonecrosis of the jaw while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid conditions like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Longer duration of bisphosphonate use also increases risk.

How is osteonecrosis of the jaw diagnosed and managed in Fosamax users?

Diagnosis is based on clinical examination and imaging showing exposed, non-healing bone in the jaw. Management includes discontinuing the bisphosphonate if severe symptoms develop, addressing local infection, and avoiding invasive dental procedures if possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.